While Neurogene Inc has underperformed by -17.55%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, NGNE fell by -81.03%, with highs and lows ranging from $74.49 to $11.02, whereas the simple moving average fell by -69.34% in the last 200 days.
On June 27, 2024, BMO Capital Markets started tracking Neurogene Inc (NASDAQ: NGNE) recommending Outperform. A report published by Robert W. Baird on June 11, 2024, Initiated its previous ‘Outperform’ rating for NGNE. Leerink Partners also rated NGNE shares as ‘Outperform’, setting a target price of $46 on the company’s shares in an initiating report dated April 29, 2024. William Blair Initiated an Outperform rating on March 21, 2024, and assigned a price target of $61. H.C. Wainwright initiated its ‘Buy’ rating for NGNE, as published in its report on January 08, 2024. Stifel’s report from January 05, 2024 suggests a price prediction of $31 for NGNE shares, giving the stock a ‘Buy’ rating. TD Cowen also rated the stock as ‘Outperform’.
Analysis of Neurogene Inc (NGNE)
One of the most important indicators of Neurogene Inc’s future performance is equity, which can be evaluated using several well-rounded types of analysis and research techniques. The goal here is to ensure that your current return on equity of -30.28% is sufficient for you to turn a profit off your investment. Taking into account the quick ratio of the company, currently set at 20.84, you can see that the company can cover any debts it may have, which can easily be seen in the annual report of the company.
For any stock, average volume can also provide valuable insight into volatility, and NGNE is recording 236.16K average volume. On a monthly basis, the volatility of the stock is set at 9.58%, whereas on a weekly basis, it is put at 17.88%, with a loss of -32.01% over the past seven days. Furthermore, long-term investors anticipate a median target price of $50.20, showing growth from the present price of $9.65, which can serve as yet another indication of whether NGNE is worth investing in or should be passed over.
How Do You Analyze Neurogene Inc Shares?
Along with the fundamentals, it is also important to consider how many employees own shares of the company. This is because the values should be in line with investors’ expectations. As such, the current holdings of company stock inside the company are set at 17.51%. This can enable you to see the extent to which executives own the company’s stock. As opposed to executive stock, institutional ownership accounts for 93.71% of the company’s shares, contributing to an indication of company value, since large shareholders may signify strength within the organization.
